natgillin/translations-raw huggingface dataset:
This will help reduce the PCV2 viraemia, virus load in the lungs and lymphoid tissue and virus shedding.
To pomaga zmanjšati viremijo, virusno breme v pljučih in limfnih tkivih ter izločanje virusa pri okužbi s PCV2.
Porcilis PCV ID contains the active substance porcine circovirus (PCV2) ORF2 subunit antigen.
Zdravilo Porcilis PCV ID vsebuje zdravilno učinkovino antigensko podenoto ORF2 prašičjega cirkovirusa (PCV2).
PCV2 infection is widespread and nearly all pig herds are infected with PCV2.
Okužba s prašičjim cirkovirusom tipa 2 je zelo pogosta, tako da so s tem okužene skoraj vse črede prašičev.
It will also help to reduce the loss of daily weight gain and mortality associated with PCV2 infection.
Prav tako se uporablja za zmanjšanje izgube dnevnega prirasta telesne mase in umrljivosti, povezanih z okužbo s prašičjim cirkovirusom tipa 2 (PCV2).
How does Porcilis PCV ID work?
Kako zdravilo Porcilis PCV ID deluje?
The vaccine is given to fattening pigs from three weeks of age as a single injection into the skin at the side of the neck, along the back or in the hind leg. Protection against PCV 2 starts two weeks after vaccination and lasts for 23 weeks after vaccination.
Zaščita pred virusom PCV2 se razvije dva tedna po cepljenju in traja 23 tednov po njem.
It is not intended to provide practical advice on how to use Porcilis PCV ID.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
How is Porcilis PCV ID used?
Za kaj se zdravilo Porcilis PCV ID uporablja?
See section 2, Do not take Efficib.
Glejte poglavje 2, Ne jemljite zdravila Efficib.
If you stop taking Efficib, your blood sugar may rise again.
Če prenehate jemati zdravilo Efficib, se vam krvni sladkor lahko ponovno poviša.
Efficib is contraindicated in patients with:
Zdravilo Efficib je kontraindicirano pri:
If no adequate strength of Efficib is available, individual monocomponents should be used instead of the fixed-dose combination.
Če ni na voljo ustrezne jakosti zdravila Efficib, je treba namesto fiksne kombinacije uporabiti posamične monokomponente.
The safety and efficacy of Efficib in children and adolescents from birth to < 18 years of age have not been established.
Varnost in učinkovitost zdravila Efficib pri otrocih in mladostnikih, od rojstva do starosti < 18 let, nista bili dokazani.
What Efficib is and what it is used for
Kaj je zdravilo Efficib in za kaj ga uporabljamo
Efficib must be discontinued at the time of surgery under general, spinal or epidural anaesthesia.
Uporabo zdravila Efficib je treba v času kirurškega posega pod splošno, spinalno ali epiduralno anestezijo prekiniti.
Your doctor may ask you to stop Efficib.
Zdravnik vam bo morda naročil, da prenehate z jemanjem zdravila Efficib.
What you need to know before you take Efficib
Kaj morate vedeti, preden boste vzeli zdravilo Efficib
STOP taking Efficib and contact a doctor immediately if you notice any of the following serious side effects:
Zdravilo Efficib takoj PRENEHAJTE jemati in se posvetujte z zdravnikom, če opazite katerega koli od naslednjih resnih neželenih učinkov:
Efficib should not be used in patients with type 1 diabetes and must not be used for the treatment of diabetic ketoacidosis.
Zdravila Efficib se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 in za zdravljenje diabetične ketoacidoze.
The European Medicines Agency has waived the obligation to submit the results of studies with Efficib in all subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Efficib za vse podskupine pediatrične populacije za sladkorno bolezen tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Other medicines and Efficib
Druga zdravila in zdravilo Efficib
During treatment with Efficib, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.
Med zdravljenjem z zdravilom Efficib bo zdravnik vsaj enkrat letno preveril delovanje ledvic, če pa ste starejša oseba in/ali se vam delovanje ledvic slabša, pa še pogosteje.
No animal studies have been conducted with Efficib.
Študij na živalih z zdravilom Efficib niso opravili.
What Efficib is and what it is used for What you need to know before you take Efficib How to take Efficib
Kaj je zdravilo Efficib in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Efficib Kako jemati zdravilo Efficib Možni neželeni učinki
Your doctor will decide when you must stop and when to restart your treatment with Efficib.
Zdravnik se bo odločil, kdaj morate z jemanjem zdravila Efficib prenehati in kdaj lahko nadaljujete.
Efficib contains two different medicines called sitagliptin and metformin.
Zdravilo Efficib vsebuje dve različni učinkovini, imenovani sitagliptin in metformin.
You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Efficib.
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Efficib.
Efficib may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly.
Zdravilo Efficib lahko povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza, zlasti če ledvice ne delujejo pravilno.
If you forget to take Efficib
Če ste pozabili vzeti zdravilo Efficib
The dose of antihyperglycaemic therapy with Efficib should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin.
Odmerek zdravila Efficib pri antidiabetičnem zdravljenju je treba prilagoditi na podlagi bolnikovega trenutnega režima zdravljenja, učinkovitosti in tolerabilnosti, pri tem pa se ne sme preseči največjega dovoljenega dnevnega odmerka 100 mg sitagliptina.
If you stop taking Efficib
Če ste prenehali jemati zdravilo Efficib
Pharmacokinetic drug interaction studies with Efficib have not been performed; however, such studies have been conducted with the individual active substances, sitagliptin and metformin.
Študije farmakokinetičnih interakcij z zdravilom Efficib niso bile izvedene, vendar pa so take študije opravili s posameznima učinkovinama, sitagliptinom in metforminom.
Efficib may cause a very rare (may affect up to 1 in 10,000 people), but very serious side effect called lactic acidosis (see section “Warnings and precautions”).
Zdravilo Efficib lahko povzroči zelo redek (pojavi se lahko pri največ 1 od 10.000 bolnikov), a zelo resen neželeni učinek, imenovan laktacidoza (glejte poglavje "Opozorila in previdnostni ukrepi").
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example, in the context of an X-ray or scan, you must stop taking Efficib before or at the time of the injection.
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Efficib.
Avoid excessive alcohol intake while taking Efficib since this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Med jemanjem zdravila Efficib ne uživajte čezmernih količin alkohola, saj lahko to poveča tveganje za laktacidozo (glejte poglavje "Opozorila in previdnostni ukrepi").
Stop taking Efficib for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal.
Za kratek čas prenehajte jemati zdravilo Efficib, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
If you need to have major surgery you must stop taking Efficib during and for some time after the procedure.
Če morate na večji kirurški poseg, morate v času posega in še nekaj časa po tem prenehati z jemanjem zdravila Efficib.
If this happens, you must stop taking Efficib and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.
V tem primeru morate prenehati jemati zdravilo Efficib in se takoj obrniti na zdravnika ali najbližjo bolnišnico, saj lahko laktacidoza vodi v komo.
The following statements reflect the pharmacokinetic properties of the individual active substances of Efficib.
V nadaljevanju so naštete farmakokinetične lastnosti posameznih učinkovin v zdravilu Efficib.
Efficib should be given twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin.
Zdravilo Efficib je treba jemati dvakrat na dan s hrano, da se zmanjšajo neželeni učinki metformina na prebavila.
What Efficib looks like and contents of the pack
Izgled zdravila Efficib in vsebina pakiranja
Change in clinical status of patients with previously controlled type 2 diabetes A patient with type 2 diabetes previously well controlled on Efficib who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Spremembe kliničnega statusa pri bolnikih s predhodno nadzorovano sladkorno boleznijo tipa 2 Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Efficib, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
Efficib with alcohol
Zdravilo Efficib skupaj z alkoholom
Stop taking Efficib and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.
Takoj prenehajte jemati zdravilo Efficib in se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
If you take more than the prescribed dosage of this medicine, contact your doctor immediately.
Če ste vzeli večji odmerek zdravila Efficib, kot bi smeli Če ste vzeli večji odmerek tega zdravila od predpisanega, se takoj posvetujte z zdravnikom.
Efficib is contraindicated in patients with GFR < 30 mL/min and should be temporarily discontinued during conditions with the potential to alter renal function (see section 4.3).
Zdravilo Efficib je kontraindicirano pri bolnikih z GFR < 30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic (glejte poglavje 4.3).
Hepatic impairment Efficib must not be used in patients with hepatic impairment (see section 5.2).
Jetrna okvara Zdravila Efficib se pri bolnikih z okvaro jeter ne sme uporabljati (glejte poglavje 5.2).
For patients switching from co-administration of sitagliptin and metformin For patients switching from co-administration of sitagliptin and metformin, Efficib should be initiated at the dose of sitagliptin and metformin already being taken.
Pri bolnikih, ki prehajajo s sočasnega jemanja sitagliptina in metformina Pri bolnikih, ki prehajajo s sočasnega jemanja sitagliptina in metformina, je treba zdravljenje z zdravilom Efficib začeti z odmerkom sitagliptina in metformina, ki ga že jemljejo.
A bioequivalence study in healthy subjects demonstrated that the Efficib (sitagliptin/metformin hydrochloride) combination tablets are bioequivalent to co-administration of sitagliptin phosphate and metformin hydrochloride as individual tablets.
V bioekvivalenčni študiji pri zdravih osebah so pokazali, da so kombinirane tablete Efficib (sitagliptin/metforminijev klorid) bioekvivalentne sočasni uporabi sitagliptinijevega fosfata in metforminijevega klorida v obliki posameznih tablet.
As metformin and sitagliptin are excreted by the kidney, Efficib should be used with caution as age increases.
Metformin in sitagliptin se izločata skozi ledvice, zato je pri uporabi zdravila Efficib pri starejših potrebna previdnost.
If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Efficib.
Če niste prepričani, če kar koli od navedenega velja za vas, se pred začetkom jemanja zdravila Efficib, posvetujte z zdravnikom ali farmacevtom.
Efficib must therefore not be used in women who are breast-feeding (see section 4.3).
Zato ženske, ki dojijo, zdravila Efficib ne smejo jemati (glejte poglavje 4.3).
Efficib should not be used during pregnancy.
Bolnice med nosečnostjo ne smejo jemati zdravila Efficib.
When Efficib is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia (see section 4.4).
Kadar se zdravilo Efficib uporablja v kombinaciji z insulinom, bo morda potreben manjši odmerek insulina za zmanjšanje tveganja za hipoglikemijo (glejte poglavje 4.4).
When Efficib is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4).
Kadar se zdravilo Efficib uporablja v kombinaciji s sulfonilsečnino, bo morda potreben manjši odmerek sulfonilsečnine za zmanjšanje tveganja za hipoglikemijo (glejte poglavje 4.4).
Patients receiving Efficib in combination with a sulphonylurea or with insulin may be at risk for hypoglycaemia.
Pri bolnikih, ki prejemajo zdravilo Efficib v kombinaciji s sulfonilsečnino ali z insulinom, se lahko pojavi tveganje za hipoglikemijo.
Efficib has no or negligible influence on the ability to drive and use machines.
Zdravilo Efficib nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
If a hypersensitivity reaction is suspected, Efficib should be discontinued, other potential causes of the event should be assessed, and alternative treatment for diabetes should be instituted (see section 4.8).
Pri sumu na preobčutljivostne reakcije morate zdravljenje z zdravilom Efficib prekiniti, oceniti druge morebitne vzroke za ta neželeni učinek in začeti zdraviti sladkorno bolezen z drugimi zdravili (glejte poglavje 4.8).
There have been no therapeutic clinical trials conducted with Efficib tablets however bioequivalence of Efficib with co-administered sitagliptin and metformin has been demonstrated (see section 5.2).
Kliničnih terapevtskih preskušanj z zdravilom Efficib niso izvedli, vendar pa so dokazali bioekvivalenco zdravila Efficib in sočasne uporabe sitagliptina in metformina (glejte poglavje 5.2).
You will need to stop taking Efficib at the time of the X-ray and for 2 or more days after as directed by your doctor,
Zdravilo Efficib morate prenehati jemati na dan rentgenskega pregleda in ga ne smete jemati še 2 ali več dni po njem, kot vam je naročil zdravnik, odvisno od delovanja vaših ledvic.
Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Zdravilo Efficib je indicirano kot dodatek dieti in telesni aktivnosti za izboljšanje urejenosti glikemije pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka samega metformina, ki ga prenašajo, ali pri bolnikih, ki že prejemajo kombinacijo sitagliptina in metformina.
Efficib must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.3 and 4.4).
Zdravilo Efficib je treba pred slikanjem ali v času slikanja ukiniti in se ga sme ponovno uvesti najmanj 48 ur pozneje, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno (glejte poglavji 4.3 in 4.4).
How to take Efficib
Kako jemati zdravilo Efficib
Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving Efficib (see section 4).
Pri bolnikih, ki so prejemali zdravilo Efficib, so poročali o primerih vnetja trebušne slinavke (pankreatitisa) (glejte poglavje 4).
What Efficib contains
Kaj vsebuje zdravilo Efficib
For the different doses on metformin, Efficib is available in strengths of 50 mg sitagliptin and 850 mg metformin hydrochloride or 1,000 mg metformin hydrochloride.
Za različne odmerke metformina je zdravilo Efficib na voljo v jakostih po 50 mg sitagliptina in 850 mg metforminijevega klorida ali 1.000 mg metforminijevega klorida.
The level of digoxin in your blood may need to be checked if taking with Efficib.
Med sočasnim jemanjem z zdravilom Efficib vam bodo morda morali preveriti vrednosti digoksina v krvi.
Efficib is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.
Zdravilo Efficib je indicirano za trojno kombinirano zdravljenje z agonistom receptorja gama, aktiviranega s peroksisomskim proliferatorjem (PPAR - peroxisome proliferator-activated receptor gamma) (tj. s tiazolidindionom) kot dodatek dieti in telesni aktivnosti pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka metformina, ki ga prenašajo, in agonista PPAR.
Efficib is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
Zdravilo Efficib je indicirano tudi kot dodatno zdravljenje k insulinu (tj. trojno kombinirano zdravljenje) kot dodatek dieti in telesni aktivnosti za izboljšanje urejenosti glikemije pri bolnikih, pri katerih s stabilnim odmerkom insulina in samim metforminom urejenost glikemije ni zadostna.
If you are not sure, talk to your doctor, pharmacist or nurse before taking Efficib.
Če niste prepričani, se pred začetkom jemanja zdravila Efficib, posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Do not take Efficib if any of the above apply to you and talk with your doctor about other ways of managing your diabetes.
Zdravila Efficib ne jemljite in se z zdravnikom posvetujte o drugih možnostih za nadzor sladkorne bolezni, če kar koli od navedenega velja za vas.
Talk to your doctor or pharmacist before taking Efficib: - if you have or have had a disease of the pancreas (such as pancreatitis) - if you have or have had gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood.
Pred začetkom jemanja zdravila Efficib se posvetujte z zdravnikom ali farmacevtom: - če imate ali ste kdaj imeli bolezen trebušne slinavke (kot je pankreatitis).
Efficib is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Zdravilo Efficib je indicirano v kombinaciji s sulfonilsečnino (tj. trojno kombinirano zdravljenje) kot dodatek dieti in telesni aktivnosti pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka metformina, ki ga prenašajo, in sulfonilsečnine.
Efficib 50 mg/1,000 mg film-coated tablets
Efficib 50 mg/1.000 mg filmsko obložene tablete
Efficib 50 mg/850 mg film-coated tablets
Efficib 50 mg/850 mg filmsko obložene tablete
If pancreatitis is suspected, Efficib and other potentially suspect medicinal products should be discontinued; if acute pancreatitis is confirmed, Efficib should not be restarted.
V primeru potrjenega akutnega pankreatitisa se zdravila Efficib ne sme ponovno uvesti.
How to store Efficib
Shranjevanje zdravila Efficib
If bullous pemphigoid is suspected, Efficib should be discontinued.
Ob sumu na bulozni pemfigoid je treba zdravljenje z zdravilom Efficib prekiniti.
EU/1/08/457/008 14 film-coated tablets EU/1/08/457/009 28 film-coated tablets EU/1/08/457/010 56 film-coated tablets EU/1/08/457/021 60 film-coated tablets EU/1/08/457/011 112 film-coated tablets EU/1/08/457/012 168 film-coated tablets EU/1/08/457/022 180 film-coated tablets EU/1/08/457/013 196 film-coated tablets EU/1/08/457/014 50 x 1 film-coated tablets EU/1/08/457/016 196 (2 x 98) film-coated tablets EU/1/08/457/018 168 (2 x 84) film-coated tablets
EU/1/08/457/008 14 filmsko obloženih tablet EU/1/08/457/009 28 filmsko obloženih tablet EU/1/08/457/010 56 filmsko obloženih tablet EU/1/08/457/021 60 filmsko obloženih tablet EU/1/08/457/011 112 filmsko obloženih tablet EU/1/08/457/012 168 filmsko obloženih tablet EU/1/08/457/022 180 filmsko obloženih tablet EU/1/08/457/013 196 filmsko obloženih tablet EU/1/08/457/014 50 x 1 filmsko obložena tableta EU/1/08/457/016 196 (2 x 98) filmsko obloženih tablet EU/1/08/457/018 168 (2 x 84) filmsko obloženih tablet
EU/1/08/457/009 EU/1/08/457/010 EU/1/08/457/011 EU/1/08/457/012 EU/1/08/457/013 EU/1/08/457/014 EU/1/08/457/016 EU/1/08/457/018 EU/1/08/457/021 EU/1/08/457/022
EU/1/08/457/008 EU/1/08/457/009 EU/1/08/457/010 EU/1/08/457/011 EU/1/08/457/012 EU/1/08/457/013 EU/1/08/457/014 EU/1/08/457/016
EU/1/08/457/001 14 film-coated tablets EU/1/08/457/002 28 film-coated tablets EU/1/08/457/003 56 film-coated tablets EU/1/08/457/019 60 film-coated tablets EU/1/08/457/004 112 film-coated tablets EU/1/08/457/005 168 film-coated tablets EU/1/08/457/020 180 film-coated tablets EU/1/08/457/006 196 film-coated tablets EU/1/08/457/007 50 x 1 film-coated tablets EU/1/08/457/015 196 (2 x 98) film-coated tablets EU/1/08/457/017 168 (2 x 84) film-coated tablets
EU/1/08/457/001 14 filmsko obloženih tablet EU/1/08/457/002 28 filmsko obloženih tablet EU/1/08/457/003 56 filmsko obloženih tablet EU/1/08/457/019 60 filmsko obloženih tablet EU/1/08/457/004 112 filmsko obloženih tablet EU/1/08/457/005 168 filmsko obloženih tablet EU/1/08/457/020 180 filmsko obloženih tablet EU/1/08/457/006 196 filmsko obloženih tablet EU/1/08/457/007 50 x 1 filmsko obložena tableta EU/1/08/457/015 196 (2 x 98) filmsko obloženih tablet EU/1/08/457/017 168 (2 x 84) filmsko obloženih tablet
Efficib 50 mg/850 mg tablets sitagliptin/metformin HCl
Efficib 50 mg/850 mg tablete sitagliptin/metformin HCl
Efficib 50 mg/1,000 mg tablets sitagliptin/metformin HCl
Efficib 50 mg/1.000 mg tablete sitagliptin/metformin HCl
Do not take Efficib: - if you are allergic to sitagliptin or metformin or any of the other ingredients of this medicine (listed in section 6) - if you have severely reduced kidney function - if you have uncontrolled diabetes, with e.g. severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see “Risk of lactic acidosis” below) or ketoacidosis.
- če imate nenadzorovano sladkorno bolezen, na primer s hudo hiperglikemijo (visoko ravnjo sladkorja v krvi), siljenjem na bruhanje, bruhanjem, drisko, hitro izgubo telesne mase, laktacidozo (glejte spodaj "Tveganje za laktacidozo") ali ketoacidozo.
In addition, patients should be alerted to the risk of hypoglycaemia when Efficib is used in combination with a sulphonylurea or with insulin.
Poleg tega je treba bolnike, ki jemljejo zdravilo Efficib skupaj s sulfonilsečnino ali z insulinom, opozoriti na tveganje za pojav hipoglikemije.
This is sometimes called insulin-dependent diabetes - if you have or have had an allergic reaction to sitagliptin, metformin, or Efficib (see section 4) - if you are taking a sulphonylurea or insulin, diabetes medicines, together with Efficib, as you may experience low blood sugar levels (hypoglycaemia).
- če imate ali ste imeli alergijsko reakcijo na sitagliptin, metformin ali zdravilo Efficib (glejte poglavje 4).
Efficib 50 mg/1,000 mg film-coated tablets sitagliptin/metformin hydrochloride
Efficib 50 mg/1.000 mg filmsko obložene tablete sitagliptin/metforminijev klorid
Efficib 50 mg/850 mg film-coated tablets sitagliptin/metformin hydrochloride
Efficib 50 mg/850 mg filmsko obložene tablete sitagliptin/metforminijev klorid